MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$21,000,000
Net Income
$3,670,000
Net Profit Margin
17.48%
EPS
$0.08
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Collaboration revenue
21,000,000
-
0
0
Research and development
6,162,000
8,181,000
11,634,000
13,143,000
General and administrative
7,680,000
5,090,000
4,092,000
4,399,000
Total operating expenses
13,842,000
13,271,000
15,726,000
17,542,000
Operating income (loss)
7,158,000
-13,271,000
-15,726,000
-17,542,000
Interest income
277,000
433,000
697,000
850,000
Interest expense
475,000
1,368,000
1,341,000
1,301,000
Loss on extinguishment of note payable
-3,354,000
-
0
0
Other income, net
64,000
674,000
0
11,000
Total other expense
-3,488,000
-261,000
-644,000
-440,000
Net income (loss)
3,670,000
-13,532,000
-16,370,000
-17,982,000
Basic EPS
0.08
-0.28
-0.36
-0.4
Diluted EPS
0.08
-0.28
-0.36
-0.4
Basic Average Shares
48,597,534
48,596,817
45,804,042
44,981,746
Diluted Average Shares
48,597,534
49,388,181
45,804,042
44,981,746
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Collaboration revenue
$21,000,000
Operating income (loss)
$7,158,000
(140.80%↑ Y/Y)
Total operating
expenses
$13,842,000
(-21.09%↓ Y/Y)
Net income (loss)
$3,670,000
(120.41%↑ Y/Y)
Total other expense
-$3,488,000
(-692.73%↓ Y/Y)
Interest income
$277,000
(-67.41%↓ Y/Y)
Other income, net
$64,000
(481.82%↑ Y/Y)
General and
administrative
$7,680,000
(74.59%↑ Y/Y)
Research and development
$6,162,000
(-53.12%↓ Y/Y)
Loss on
extinguishment of note payable
-$3,354,000
Interest expense
$475,000
(-63.49%↓ Y/Y)
Buy us a coffee
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)